Connect your AI

Opus Genetics IRD Warrants and Rights Outstanding

Warrants and Rights Outstanding at other companies

Nuvation BioNUVB

5.8M0.0%

KEE

Keel Infrastructure Corp. Common StockKEEL

2.2M—

Unusual MachinesUMAC

0-100%

KRAKacquisition KRAQ

0—

The RealRealREAL

7.9M—

NuScale PowerSMR

0-100%

Other financials

Income statement

Revenue$2.2M-50.6%

Operating income-$14.4M-44.7%

Net income-$65.5M-700%

EPS (diluted)-$0.75-213%

Balance sheet

Cash & equivalents$60.0M+43.5%

Total debt$1.2M—

Total equity-$45.8M-1,004%

Total assets$66.8M+38.7%

Cash flow

Operating cash flow-$12.7M-41.5%

Valuation

Market cap$307.14M+442%

Enterprise value$248.38M—

P/S25.6×+21.5×

Profitability

Operating margin-359.1%-68.9pp

Net margin-892.4%-12,322pp

Returns & leverage

Return on equity-449.4%-2,573pp

Debt / equity0.1×—

Current ratio7.1×+5.2×

Where this comes from

Reported directly by Opus Genetics in its filing.

Tagged under the XBRL concept us-gaap:ClassOfWarrantOrRightOutstanding.

The official record: Opus Genetics’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Opus Genetics's warrants and rights outstanding.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Opus Genetics's warrants and rights outstanding?: Opus Genetics (IRD) reported warrants and rights outstanding of 22.9M in Q1 2026.